Celularity (CELU) Competitors $2.15 +0.11 (+5.39%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$2.20 +0.05 (+2.33%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELU vs. SGMT, AVIR, VOR, OGI, PRQR, HRTX, TRDA, CABA, ACRS, and VTYXShould you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Sagimet Biosciences (SGMT), Atea Pharmaceuticals (AVIR), Vor Biopharma (VOR), Organigram Global (OGI), ProQR Therapeutics (PRQR), Heron Therapeutics (HRTX), Entrada Therapeutics (TRDA), Cabaletta Bio (CABA), Aclaris Therapeutics (ACRS), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical products" industry. Celularity vs. Its Competitors Sagimet Biosciences Atea Pharmaceuticals Vor Biopharma Organigram Global ProQR Therapeutics Heron Therapeutics Entrada Therapeutics Cabaletta Bio Aclaris Therapeutics Ventyx Biosciences Sagimet Biosciences (NASDAQ:SGMT) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation. Is SGMT or CELU more profitable? Sagimet Biosciences has a net margin of 0.00% compared to Celularity's net margin of -165.22%. Sagimet Biosciences' return on equity of -39.88% beat Celularity's return on equity.Company Net Margins Return on Equity Return on Assets Sagimet BiosciencesN/A -39.88% -38.40% Celularity -165.22%-459.57%-57.71% Do institutionals & insiders hold more shares of SGMT or CELU? 87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 22.1% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, SGMT or CELU? Sagimet Biosciences has a beta of 3.23, suggesting that its stock price is 223% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Do analysts prefer SGMT or CELU? Sagimet Biosciences presently has a consensus price target of $25.67, suggesting a potential upside of 251.12%. Celularity has a consensus price target of $6.00, suggesting a potential upside of 179.07%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Sagimet Biosciences is more favorable than Celularity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger earnings and valuation, SGMT or CELU? Sagimet Biosciences has higher earnings, but lower revenue than Celularity. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSagimet Biosciences$2M118.86-$45.57M-$1.83-3.99Celularity$54.22M1.06-$57.89M-$3.18-0.68 Does the media refer more to SGMT or CELU? In the previous week, Sagimet Biosciences had 10 more articles in the media than Celularity. MarketBeat recorded 11 mentions for Sagimet Biosciences and 1 mentions for Celularity. Celularity's average media sentiment score of 1.11 beat Sagimet Biosciences' score of 0.53 indicating that Celularity is being referred to more favorably in the news media. Company Overall Sentiment Sagimet Biosciences Positive Celularity Positive SummarySagimet Biosciences beats Celularity on 12 of the 16 factors compared between the two stocks. Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELU vs. The Competition Export to ExcelMetricCelularityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.45M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-0.6821.5785.3527.60Price / Sales1.06271.49539.78202.41Price / CashN/A47.1237.9261.55Price / Book5.8110.1413.016.76Net Income-$57.89M-$52.31M$3.30B$275.88M7 Day Performance5.39%5.14%4.34%2.81%1 Month Performance-4.87%14.68%9.49%9.24%1 Year Performance-11.89%30.98%84.83%35.42% Celularity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELUCelularity2.2347 of 5 stars$2.15+5.4%$6.00+179.1%-9.3%$54.45M$54.22M-0.68220News CoveragePositive NewsAnalyst ForecastGap UpSGMTSagimet Biosciences2.8483 of 5 stars$6.92-5.7%$25.67+270.9%+84.4%$238.71M$2M-3.788Analyst ForecastAVIRAtea Pharmaceuticals1.9047 of 5 stars$2.92-0.3%$6.00+105.5%-9.1%$232.52MN/A-1.8170News CoveragePositive NewsAnalyst ForecastVORVor Biopharma3.2274 of 5 stars$39.89+18.6%N/AN/A$230.43MN/A-0.15140Analyst ForecastInsider TradeHigh Trading VolumeOGIOrganigram Global0.7257 of 5 stars$1.97+16.6%N/A+14.1%$227.04M$117.47M39.41860Analyst ForecastHigh Trading VolumePRQRProQR Therapeutics2.2597 of 5 stars$2.19+3.8%$8.00+265.3%+26.2%$222M$20.46M-4.76180News CoveragePositive NewsAnalyst ForecastHRTXHeron Therapeutics3.5421 of 5 stars$1.27+5.0%$4.50+254.3%-29.7%$221.81M$149.69M-63.50300News CoverageAnalyst ForecastTRDAEntrada Therapeutics3.2563 of 5 stars$5.84+0.7%$25.67+339.5%-62.4%$220.62M$79.48M-3.28110News CoveragePositive NewsAnalyst ForecastCABACabaletta Bio2.7666 of 5 stars$2.38+0.8%$14.50+509.2%-44.5%$215.86MN/A-0.8850Analyst ForecastACRSAclaris Therapeutics2.0094 of 5 stars$1.92-3.5%$8.71+353.9%+63.8%$215.58M$18.72M-1.40100Gap UpVTYXVentyx Biosciences1.2015 of 5 stars$3.03+1.7%$7.50+147.5%+86.8%$212.50MN/A-1.8030News CoverageAnalyst Forecast Related Companies and Tools Related Companies SGMT Competitors AVIR Competitors VOR Competitors OGI Competitors PRQR Competitors HRTX Competitors TRDA Competitors CABA Competitors ACRS Competitors VTYX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELU) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
